Pages that link to "Q43230436"
Jump to navigation
Jump to search
The following pages link to Paliperidone palmitate maintenance treatment in delaying the time-to-relapse in patients with schizophrenia: a randomized, double-blind, placebo-controlled study. (Q43230436):
Displaying 50 items.
- Maintenance treatment with antipsychotic drugs for schizophrenia (Q24197902) (← links)
- Paliperidone palmitate for schizophrenia (Q24202846) (← links)
- Critical appraisal of 3-monthly paliperidone depot injections in the treatment of schizophrenia (Q26745792) (← links)
- A critical appraisal of paliperidone long-acting injection in the treatment of schizoaffective disorder (Q26766541) (← links)
- Profile of paliperidone palmitate once-monthly long-acting injectable in the management of schizophrenia: long-term safety, efficacy, and patient acceptability - a review (Q28084899) (← links)
- Antipsychotic drugs versus placebo for relapse prevention in schizophrenia: a systematic review and meta-analysis (Q28266069) (← links)
- The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review. (Q33619940) (← links)
- Efficacy and Safety of Brexpiprazole (OPC-34712) as Maintenance Treatment in Adults with Schizophrenia: a Randomized, Double-Blind, Placebo-Controlled Study (Q33625354) (← links)
- Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety (Q33802918) (← links)
- Onset of efficacy and tolerability following the initiation dosing of long-acting paliperidone palmitate: post-hoc analyses of a randomized, double-blind clinical trial (Q33898356) (← links)
- Once-monthly paliperidone injection for the treatment of schizophrenia (Q34123015) (← links)
- A one-year prospective study of the safety, tolerability and pharmacokinetics of the highest available dose of paliperidone palmitate in patients with schizophrenia (Q34210712) (← links)
- World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects (Q34315836) (← links)
- A Prospective Study Comparing the Long-term Effectiveness of Injectable Risperidone Long-acting Therapy and Oral Aripiprazole in Patients with Schizophrenia (Q34444162) (← links)
- Body weight and metabolic adverse effects of asenapine, iloperidone, lurasidone and paliperidone in the treatment of schizophrenia and bipolar disorder: a systematic review and exploratory meta-analysis (Q34641561) (← links)
- Withdrawal symptoms and rebound syndromes associated with switching and discontinuing atypical antipsychotics: theoretical background and practical recommendations. (Q34653803) (← links)
- Incidence of tardive dyskinesia: a comparison of long-acting injectable and oral paliperidone clinical trial databases (Q34693244) (← links)
- Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review (Q34775426) (← links)
- Onset of efficacy with acute long-acting injectable paliperidone palmitate treatment in markedly to severely ill patients with schizophrenia: post hoc analysis of a randomized, double-blind clinical trial (Q34855041) (← links)
- Body mass index and metabolic parameters in patients with schizophrenia during long-term treatment with paliperidone palmitate (Q35100107) (← links)
- Efficacy, safety, and impact on hospitalizations of paliperidone palmitate in recent-onset schizophrenia (Q35186007) (← links)
- High relapse rate and poor medication adherence in the Chinese population with schizophrenia: results from an observational survey in the People's Republic of China (Q35605892) (← links)
- Efficacy and safety of flexibly dosed paliperidone palmitate in Chinese patients with acute schizophrenia: an open-label, single-arm, prospective, interventional study (Q35794615) (← links)
- The cost reduction in hospitalization associated with paliperidone palmitate in the People's Republic of China, Korea, and Malaysia (Q35934874) (← links)
- Efficacy, tolerability, and safety of aripiprazole once-monthly versus other long-acting injectable antipsychotic therapies in the maintenance treatment of schizophrenia: a mixed treatment comparison of double-blind randomized clinical trials (Q36001512) (← links)
- The Potential Role of Long-acting Injectable Antipsychotics in People with Schizophrenia and Comorbid Substance Use. (Q36059843) (← links)
- Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychotics (Q36121675) (← links)
- Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults (Q36144552) (← links)
- Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece (Q36198389) (← links)
- Long-term tolerability of once-monthly injectable paliperidone palmitate in subjects with recently diagnosed schizophrenia (Q36202865) (← links)
- Paliperidone palmitate and risperidone long-acting injectable in subjects with schizophrenia recently treated with oral risperidone or other oral antipsychotics (Q36672952) (← links)
- Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France (Q36698856) (← links)
- Once-monthly paliperidone palmitate in recently diagnosed and chronic non-acute patients with schizophrenia (Q36981526) (← links)
- Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies (Q37042180) (← links)
- Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder (Q37063242) (← links)
- Tolerability of initiation doses of once-monthly paliperidone palmitate in patients with recently diagnosed schizophrenia in an acute treatment trial (Q37078993) (← links)
- Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study (Q37137799) (← links)
- Pharmacoeconomic comparison of aripiprazole once-monthly and paliperidone palmitate from a head-to-head clinical trial in schizophrenia: a US analysis (Q37280123) (← links)
- Paliperidone Palmitate Treatment in Outpatient Care Setting: A Naturalistic Study (Q37299914) (← links)
- Prolactin Levels After Switching to Paliperidone Palmitate in Patients with Schizophrenia (Q37361982) (← links)
- Randomized, placebo-controlled, double-blind study assessing the efficacy and safety of paliperidone palmitate in Asian patients with schizophrenia (Q37390749) (← links)
- Extended-release intramuscular paliperidone palmitate: a review of its use in the treatment of schizophrenia (Q38008704) (← links)
- A review of paliperidone palmitate (Q38067137) (← links)
- Long-acting injectable antipsychotics in early psychosis: a literature review (Q38076170) (← links)
- Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective (Q38115487) (← links)
- New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia (Q38125213) (← links)
- Onset and persistence of efficacy by symptom domain with long-acting injectable paliperidone palmitate in patients with schizophrenia (Q38206231) (← links)
- The quality of reporting of phase II and III trials for new antipsychotics: a systematic review (Q38234325) (← links)
- Weight gain and antipsychotics: a drug safety review (Q38268590) (← links)
- Treatment effect with paliperidone palmitate compared with oral antipsychotics in patients with recent-onset versus more chronic schizophrenia and a history of criminal justice system involvement (Q38403164) (← links)